Diffuse large B-cell lymphoma: Is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy?

Chadi Nabhan*, Jayesh Mehta

*Corresponding author for this work

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

While rituximab-based chemo-immunotherapy has improved response and long-term survival rates in diffuse large B-cell non-Hodgkin lymphoma (DLBCL), relapse and death from recurrent disease is still the eventual outcome in a significant proportion of patients, especially those with high-risk disease. Autologous hematopoietic stem cell transplant (AHSCT) in first remission, which was studied mainly before the advent of rituximab, has lost its appeal due to several small negative trials. However, definitive data do not exist to determine the role of AHSCT in first remission. In this review, we critically evaluate studies investigating AHSCT in DLBCL in first remission. Most available studies have shortcomings that limit the applicability of their findings. AHSCT in first remission may have a role in selected patients with high-risk DLBCL, but a carefully designed prospective study is required to appropriately evaluate this concept.

Original languageEnglish (US)
Pages (from-to)1859-1866
Number of pages8
JournalLeukemia and Lymphoma
Volume53
Issue number10
DOIs
StatePublished - Oct 1 2012

Keywords

  • Bone marrow transplant
  • Clinical results
  • Large cell lymphoma
  • Lymphoma and Hodgkin disease
  • Stem cell transplant

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Diffuse large B-cell lymphoma: Is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy?'. Together they form a unique fingerprint.

  • Cite this